Our perspectives
in one place
Topic
Selected filters
Clear
News
See allOpen letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda
On 9 April 2024, IFPMA, Interfarma, and FIFARMA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda. The letter is available for download in English, Portuguese, and Spanish.
Read moreBiopharmaceutical CEO Roundtable gathers in Athens, focusing on global health challenges and role of pharmaceutical innovation
The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in April, Greece, on 3 and 4 April 2024, to discuss global health challenges and public health policies impacting biomedical innovation. 05 April 2024, Athens – The CEOs of leading biopharmaceutical companies met in Athens, Greece, to discuss collaborative solutions that can...
Read moreEnhanced collaboration between anti-doping agency and big pharma bolsters support for clean sport among athletes
On 3 April 2024 in Athens, the International Federationof Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a joint letter of intent.
Read more9th Meeting of the Intergovernmental Negotiating Body (INB): Open session with relevant stakeholders focusing on critical elements for a pandemic agreement
On 21 March 2024, Thomas Cueni, Director General, IFPMA delivered a statement at the 9th Meeting of the INB in an open session with relevant stakeholders focusing on critical elements for a pandemic agreement. IFPMA strongly supports the efforts to find agreement on a Pandemic Accord and we reaffirm our full commitment to constructively...
Read more9th Meeting of the Intergovernmental Negotiating Body (INB)
On 18 March 2024, IFPMA submitted and delivered statements at the 9th Meeting of the Intergovernmental Negotiating Body (INB). The full submitted statement is below.
Read moreDelivering equitable access in pandemics: Biopharmaceutical industry commitments
In response to the threat of future global pandemics, the biopharmaceutical industry developed a set of commitments for equitable access to essential medical countermeasures in future pandemics.
Read morePublications
See allHow we are contributing to global pharmaceutical standards
The evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...
Read more
The socio-economic value of adult immunisation programmes
Download this OHE report, commissioned by IFPMA, to learn more about the socio-economic value of adult vaccination programems on individual lives and societies at large.
Read more
Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future
This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.
Read more
Expert insights
See all
Advancing regulatory reliance on a global scale
Read more
Ageing society: Why adult immunisation delivers health and societal benefits
Read more
Access to medicines and vaccines is about much more than price
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Read more